Multiple Myeloma Market
Multiple Myeloma Market - Global Industry Assessment & Forecast
#
Pages:
147
Base Year:
2022
May - 2023
Format:
Report Code:
VMR-2142
Segments Covered
By
Drug Class Immunomodulators, Proteasome Inhibitor, Anti-CD38 Monoclonal Antibody, Alkylating Agents, Other Drug Classes
-
By
Distribution Channel Hospital Pharmacies, Retail Pharmacies & Drug Stores, Online Pharmacies
-
By
Region North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Snapshot
 Base Year:
|
2022 |
| Forecast
Years:
|
2023 - 2030 |
 Historical
Years:
|
2017 - 2021 |
 Revenue
2022: |
USD 21.6 Billion |
 Revenue 2030:
|
USD 33.1 Billion |
 Revenue CAGR
(2023 - 2030): |
6.3% |
Fastest Growing Region (2023 -
2030)
|
Asia Pacific |
Largest Region (2022):
|
North America |
Customization Offered
Cross-segment Market Size and
Analysis
for Mentioned Segments- Additional Company Profiles (Upto 5
With
No Cost)
- Additional Countries (Apart From
Mentioned Countries)
- Country/Region-specific Report
- Go To Market Strategy
- Region Specific Market Dynamics
- Region Level Market Share
- Import Export Analysis
- Production Analysis
- Others Request
Customization Speak To
Analyst
Multiple Myeloma Market Segment Analysis
- Multiple Myeloma Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
- Immunomodulators
- Proteasome Inhibitor
- Anti-CD38 Monoclonal Antibody
- Alkylating Agents
- Other Drug Classes
- Multiple Myeloma Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
- Hospital Pharmacies
- Retail Pharmacies & Drug Stores
- Online Pharmacies
-
Regional Outlook (Revenue, USD Billion/Million, 2018 - 2030)
- North America
-
North America Multiple Myeloma Market, by Drug Class
- Immunomodulators
- Proteasome Inhibitor
- Anti-CD38 Monoclonal Antibody
- Alkylating Agents
- Other Drug Classes
-
North America Multiple Myeloma Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies & Drug Stores
- Online Pharmacies
- U.S.
- U.S. Multiple Myeloma Market, by Drug Class
- Immunomodulators
- Proteasome Inhibitor
- Anti-CD38 Monoclonal Antibody
- Alkylating Agents
- Other Drug Classes
- U.S. Multiple Myeloma Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies & Drug Stores
- Online Pharmacies
- U.S. Multiple Myeloma Market, by Drug Class
- Canada
- Canada Multiple Myeloma Market, by Drug Class
- Immunomodulators
- Proteasome Inhibitor
- Anti-CD38 Monoclonal Antibody
- Alkylating Agents
- Other Drug Classes
- Canada Multiple Myeloma Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies & Drug Stores
- Online Pharmacies
- Canada Multiple Myeloma Market, by Drug Class
-
Mexico
- Mexico Multiple Myeloma Market, by Drug Class
- Immunomodulators
- Proteasome Inhibitor
- Anti-CD38 Monoclonal Antibody
- Alkylating Agents
- Other Drug Classes
- Mexico Multiple Myeloma Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies & Drug Stores
- Online Pharmacies
- Mexico Multiple Myeloma Market, by Drug Class
-
North America Multiple Myeloma Market, by Drug Class
- Europe
-
Europe Multiple Myeloma Market, by Drug Class
- Immunomodulators
- Proteasome Inhibitor
- Anti-CD38 Monoclonal Antibody
- Alkylating Agents
- Other Drug Classes
-
Europe Multiple Myeloma Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies & Drug Stores
- Online Pharmacies
- U. K.
- U.K. Multiple Myeloma Market, by Drug Class
- Immunomodulators
- Proteasome Inhibitor
- Anti-CD38 Monoclonal Antibody
- Alkylating Agents
- Other Drug Classes
- U.K. Multiple Myeloma Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies & Drug Stores
- Online Pharmacies
- U.K. Multiple Myeloma Market, by Drug Class
- France
- France Multiple Myeloma Market, by Drug Class
- Immunomodulators
- Proteasome Inhibitor
- Anti-CD38 Monoclonal Antibody
- Alkylating Agents
- Other Drug Classes
- France Multiple Myeloma Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies & Drug Stores
- Online Pharmacies
- France Multiple Myeloma Market, by Drug Class
-
Germany
- Germany Multiple Myeloma Market, by Drug Class
- Immunomodulators
- Proteasome Inhibitor
- Anti-CD38 Monoclonal Antibody
- Alkylating Agents
- Other Drug Classes
- Germany Multiple Myeloma Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies & Drug Stores
- Online Pharmacies
- Germany Multiple Myeloma Market, by Drug Class
-
Italy
- Italy Multiple Myeloma Market, by Drug Class
- Immunomodulators
- Proteasome Inhibitor
- Anti-CD38 Monoclonal Antibody
- Alkylating Agents
- Other Drug Classes
- Italy Multiple Myeloma Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies & Drug Stores
- Online Pharmacies
- Italy Multiple Myeloma Market, by Drug Class
-
Spain
- Spain Multiple Myeloma Market, by Drug Class
- Immunomodulators
- Proteasome Inhibitor
- Anti-CD38 Monoclonal Antibody
- Alkylating Agents
- Other Drug Classes
- Spain Multiple Myeloma Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies & Drug Stores
- Online Pharmacies
- Spain Multiple Myeloma Market, by Drug Class
-
Rest of Europe
- Rest of Europe Multiple Myeloma Market, by Drug Class
- Immunomodulators
- Proteasome Inhibitor
- Anti-CD38 Monoclonal Antibody
- Alkylating Agents
- Other Drug Classes
- Rest of Europe Multiple Myeloma Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies & Drug Stores
- Online Pharmacies
- Rest of Europe Multiple Myeloma Market, by Drug Class
-
Europe Multiple Myeloma Market, by Drug Class
- Asia Pacific
-
Asia Pacific Multiple Myeloma Market, by Drug Class
- Immunomodulators
- Proteasome Inhibitor
- Anti-CD38 Monoclonal Antibody
- Alkylating Agents
- Other Drug Classes
-
Asia Pacific Multiple Myeloma Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies & Drug Stores
- Online Pharmacies
- China
- China Multiple Myeloma Market, by Drug Class
- Immunomodulators
- Proteasome Inhibitor
- Anti-CD38 Monoclonal Antibody
- Alkylating Agents
- Other Drug Classes
- China Multiple Myeloma Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies & Drug Stores
- Online Pharmacies
- China Multiple Myeloma Market, by Drug Class
- Japan
- Japan Multiple Myeloma Market, by Drug Class
- Immunomodulators
- Proteasome Inhibitor
- Anti-CD38 Monoclonal Antibody
- Alkylating Agents
- Other Drug Classes
- Japan Multiple Myeloma Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies & Drug Stores
- Online Pharmacies
- Japan Multiple Myeloma Market, by Drug Class
-
Germany
- Germany Multiple Myeloma Market, by Drug Class
- Immunomodulators
- Proteasome Inhibitor
- Anti-CD38 Monoclonal Antibody
- Alkylating Agents
- Other Drug Classes
- Germany Multiple Myeloma Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies & Drug Stores
- Online Pharmacies
- Germany Multiple Myeloma Market, by Drug Class
-
India
- India Multiple Myeloma Market, by Drug Class
- Immunomodulators
- Proteasome Inhibitor
- Anti-CD38 Monoclonal Antibody
- Alkylating Agents
- Other Drug Classes
- India Multiple Myeloma Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies & Drug Stores
- Online Pharmacies
- India Multiple Myeloma Market, by Drug Class
-
South Korea
- South Korea Multiple Myeloma Market, by Drug Class
- Immunomodulators
- Proteasome Inhibitor
- Anti-CD38 Monoclonal Antibody
- Alkylating Agents
- Other Drug Classes
- South Korea Multiple Myeloma Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies & Drug Stores
- Online Pharmacies
- South Korea Multiple Myeloma Market, by Drug Class
-
South East Asia
- South East Asia Multiple Myeloma Market, by Drug Class
- Immunomodulators
- Proteasome Inhibitor
- Anti-CD38 Monoclonal Antibody
- Alkylating Agents
- Other Drug Classes
- South East Asia Multiple Myeloma Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies & Drug Stores
- Online Pharmacies
- South East Asia Multiple Myeloma Market, by Drug Class
-
Rest of Asia Pacific
- Rest of Asia Pacific Multiple Myeloma Market, by Drug Class
- Immunomodulators
- Proteasome Inhibitor
- Anti-CD38 Monoclonal Antibody
- Alkylating Agents
- Other Drug Classes
- Rest of Asia Pacific Multiple Myeloma Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies & Drug Stores
- Online Pharmacies
- Rest of Asia Pacific Multiple Myeloma Market, by Drug Class
-
Asia Pacific Multiple Myeloma Market, by Drug Class
- Latin America
-
Latin America Multiple Myeloma Market, by Drug Class
- Immunomodulators
- Proteasome Inhibitor
- Anti-CD38 Monoclonal Antibody
- Alkylating Agents
- Other Drug Classes
-
Latin America Multiple Myeloma Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies & Drug Stores
- Online Pharmacies
- Brazil
- Brazil Multiple Myeloma Market, by Drug Class
- Immunomodulators
- Proteasome Inhibitor
- Anti-CD38 Monoclonal Antibody
- Alkylating Agents
- Other Drug Classes
- Brazil Multiple Myeloma Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies & Drug Stores
- Online Pharmacies
- Brazil Multiple Myeloma Market, by Drug Class
- Argentina
- Argentina Multiple Myeloma Market, by Drug Class
- Immunomodulators
- Proteasome Inhibitor
- Anti-CD38 Monoclonal Antibody
- Alkylating Agents
- Other Drug Classes
- Argentina Multiple Myeloma Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies & Drug Stores
- Online Pharmacies
- Argentina Multiple Myeloma Market, by Drug Class
-
Rest of Latin America
- Rest of Latin America Multiple Myeloma Market, by Drug Class
- Immunomodulators
- Proteasome Inhibitor
- Anti-CD38 Monoclonal Antibody
- Alkylating Agents
- Other Drug Classes
- Rest of Latin America Multiple Myeloma Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies & Drug Stores
- Online Pharmacies
- Rest of Latin America Multiple Myeloma Market, by Drug Class
-
Latin America Multiple Myeloma Market, by Drug Class
- Middle East & Africa
-
Middle East & Africa Multiple Myeloma Market, by Drug Class
- Immunomodulators
- Proteasome Inhibitor
- Anti-CD38 Monoclonal Antibody
- Alkylating Agents
- Other Drug Classes
-
Middle East & Africa Multiple Myeloma Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies & Drug Stores
- Online Pharmacies
- GCC Countries
- GCC Countries Multiple Myeloma Market, by Drug Class
- Immunomodulators
- Proteasome Inhibitor
- Anti-CD38 Monoclonal Antibody
- Alkylating Agents
- Other Drug Classes
- GCC Countries Multiple Myeloma Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies & Drug Stores
- Online Pharmacies
- GCC Countries Multiple Myeloma Market, by Drug Class
- South Africa
- South Africa Multiple Myeloma Market, by Drug Class
- Immunomodulators
- Proteasome Inhibitor
- Anti-CD38 Monoclonal Antibody
- Alkylating Agents
- Other Drug Classes
- South Africa Multiple Myeloma Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies & Drug Stores
- Online Pharmacies
- South Africa Multiple Myeloma Market, by Drug Class
-
Rest of Middle East & Africa
- Rest of Middle East & Africa Multiple Myeloma Market, by Drug Class
- Immunomodulators
- Proteasome Inhibitor
- Anti-CD38 Monoclonal Antibody
- Alkylating Agents
- Other Drug Classes
- Rest of Middle East & Africa Multiple Myeloma Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies & Drug Stores
- Online Pharmacies
- Rest of Middle East & Africa Multiple Myeloma Market, by Drug Class
-
Middle East & Africa Multiple Myeloma Market, by Drug Class
- North America
Vantage Market
Research | 24-May-2023
FAQ
Frequently Asked Question
What is the global demand for Multiple Myeloma in terms of revenue?
-
The global Multiple Myeloma valued at USD 21.6 Billion in 2022 and is expected to reach USD 33.1 Billion in 2030 growing at a CAGR of 6.3%.
Which are the prominent players in the market?
-
The prominent players in the market are Takeda Pharmaceutical Company Limited (Japan), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), Bristol Myers Squibb Company (U.S.), Amgen Inc. (U.S.), ONO Pharmaceutical Co. Ltd. (Japan), Janssen Pharmaceuticals Inc. (Belgium), AbbVie Inc. (U.S.), Sanofi (Paris), Kary pharm (U.S.).
At what CAGR is the market projected to grow within the forecast period?
-
The market is project to grow at a CAGR of 6.3% between 2023 and 2030.
What are the driving factors fueling the growth of the market.
-
The driving factors of the Multiple Myeloma include
- Increasing Prevalence of Multiple Myeloma to Augment Market Growth
Which region accounted for the largest share in the market?
-
North America was the leading regional segment of the Multiple Myeloma in 2022.
